News Quantified

DSNKY – daiichi sankyo s/adr (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

DESTINY-Endometrial02 Phase 3 Trial of ENHERTU® Initiated as Adjuvant Therapy in Patients with HER2 Expressing Endometrial Cancer [Yahoo! Finance]

DESTINY-Endometrial02 Phase 3 Trial of ENHERTU® Initiated as Adjuvant Therapy in Patients with HER2 Expressing Endometrial Cancer

ENHERTU® Granted Breakthrough Therapy Designation in the U.S. as Post-Neoadjuvant Therapy for Patients with HER2 Positive Early Breast Cancer

Asian Market Stocks That May Be Trading Below Estimated Value In December 2025 [Yahoo! Finance]

3 Asian Stocks That Investors Might Be Undervaluing By Up To 35.8% [Yahoo! Finance]

Top News Gainers

7/31 Q1/2019 6/30/2019 EPS 66.770 ZacksConsensus N/A ActVsEst N/A - N/A 7.6%

7/31 Q1/2019 6/30/2019 EPS 66.770 ZacksConsensus N/A ActVsEst N/A - N/A 1.9%

5/8 AstraZeneca-Daiichi Sankyo breast cancer drug shows promise [Reuters] 1.8%

12/20 AstraZeneca, Daiichi's breast cancer drug gets accelerated approval from FDA [Reuters] 0.9%

12/11 AstraZeneca-Daiichi drug halts cancer for months in first readout [Reuters] 0.9%

5/14 FDA advisory panel votes against Daiichi Sankyo's blood cancer treatment [Reuters (UK)] 0.7%

2/11 Daiichi Sankyo Is Not A Buy Now [Seeking Alpha] 0.7%

8/2 UPDATE 1-U.S. FDA approves Daiichi Sankyo's treatment for rare joint tumor [Reuters] 0.5%

8/1 Q1/2019 6/30/2019 EPS 66.770 ZacksConsensus N/A ActVsEst N/A - N/A 0.5%

8/29 Positive Results Highlight Potential of Bempedoic Acid / Ezetimibe Combination for Hypercholesterolaemia with Type 2 Diabetes 0.4%

Top News Decliners

12/17 Japan shares edge lower on lacklustre export data, profit-taking [Reuters] -5.4%

6/21 FDA declines to approve Daiichi Sankyo's blood cancer treatment [Reuters] -4.6%

4/1 Concert Pharma outlines late-stage CTP-543 trials in Alopecia Areata [Seeking Alpha] -2.7%

12/9 DAIICHI SANKYO/S (OTCMKTS: DSNKY) is now covered by analysts at Jefferies Financial Group Inc. They set a "buy" rating on the stock. -2.6%

2/20 Esperion's Multiple Positives, And Other News: The Good, Bad And Ugly Of Biopharma [Seeking Alpha] -1.5%

8/12 Daiichi Sankyo, Inc. Appoints Simon King as Chief People Officer across U.S. Divisions -1.1%

1/27 Phase 2 DESTINY-Gastric01 Trial of DS-8201 Versus Chemotherapy Met Primary Endpoint -1.0%

5/14 Precision NanoSystems Signs License Agreement with Daiichi Sankyo for Use of the NanoAssemblr GMP System for Development and Manufacture of Nanomedicines [Canadian Business Journal (Canada)] -0.4%

6/13 Dr. Nicole Saphier: Why Biden's vow to 'cure cancer' if elected received so much backlash [FOX News] -0.3%

8/2 U.S. FDA approves Daiichi Sankyo's treatment for rare joint tumor [Reuters (UK)] -0.3%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day